ArticleMedicine2026
The role of visceral obesity surrogate markers in predicting cardiovascular disease: Insights from the CHARLS study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) has been a major cause of morbidity and mortality in the world, accounting for approximately one-third of all deaths worldwide. Early detection of risk factors and effective preventive measures are crucial for reducing the impact of cardiovascular and cerebrovascular diseases on public health. We conducted a retrospective analysis of data from the China Health and Retirement Longitudinal Study between 2011 and 2018. Logistic regression and restricted cubic spline modeling were used for analysis. Moreover, the area under the receiver operating characteristic curve (AUC) and its 95% confidence interval (CI) was calculated to assess the predictive power of Chinese visceral adiposity index (CVAI), lipid accumulation product (LAP), metabolic score for visceral fat (METS-VF), triglyceride-glucose (TyG), and triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) for risk of CVD. CVAI and METS-VF were significantly associated with CVD risk, with odds ratios calculated per 1 standard deviation (CVAI: odds ratio [OR] = 1.16, 95% CI 1.05-1.29; METS-VF: OR = 1.11, 95% CI 1.01-1.23). LAP (Q3: OR = 1.39, 95% CI 1.11-1.73) and TG/HDL-C ratio (Q3: OR = 1.31, 95% CI 1.08-1.59) showed significant associations with increased CVD risk. For discrimination, CVAI showed the highest AUC values, 0.5767 (0.5560-0.5974) for HD, 0.6123 (0.5873-0.6373) for stroke, 0.5910 (0.5726-0.6093) for CVD, respectively. CVAI and METS-VF were positively associated with CVD risk and showed slightly better discrimination than other adiposity-related indices. These findings suggest that visceral adiposity and dyslipidemia remain important correlates of cardiovascular and cerebrovascular risk and may inform prevention strategies when considered alongside established risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.